Targeting dendritic cells for improved HIV-1 vaccines

Advances in Experimental Medicine and Biology

Volumn 762, Issue , 2013, Pages 263-288

  Smed Sörensen, Anna ^a   Loré, Karin ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; AS 04; CPG OLIGODEOXYNUCLEOTIDE; GAG PROTEIN; GLYCOPROTEIN GP 120; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLAMMASOME; INFLUENZA VACCINE; LECTIN RECEPTOR; MIFAMURTIDE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADENOVIRUS; ADENOVIRUS 35; ADENOVIRUS 5; ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CROSS PROTECTION; DENDRITIC CELL; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INTERFERON PRODUCTION; INTERNALIZATION; MYELOID DENDRITIC CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; DENDRITIC CELLS; GENETIC VECTORS; HIV ANTIBODIES; HIV-1; HUMANS;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869023236     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4433-6-10     Document Type: Article

References (158)

1. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mans field KG, Goudsmit J, Havenga MJ, Barouch DH (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81(9):4654-4663 (Pubitemid 46668663)
2. Abel K, Wang Y, Fritts L, Sanchez E, Chung E, Fitzgerald-Bocarsly P, Krieg AM, Miller CJ (2005) Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol 12(5):606-621 (Pubitemid 41184721)
3. Adams WC, Bond E, Havenga MJ, Holterman L, Goudsmit J, Karlsson Hedestam GB, Koup RA, Lore K (2009) Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. J Gen Virol 90(Pt 7):1600-1610
4. Adams WC, Gujer C, McInerney G, Gall JG, Petrovas C, Karlsson Hedestam GB, Koup RA, Lore K (2011) Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proc Natl Acad Sci U S A 108(18):7499-7504
5. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM (2004) Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199(6):775-784 (Pubitemid 38375197)
6. Arnberg N (2009) Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 19(3):165-178
7. Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, Henn V, Kloetzel PM, Gurka S, Kroczek RA (2010) Superior antigen cross-presentation and XCR1 expression de fi ne human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 207(6):1273-1281
8. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673): 245-252 (Pubitemid 28155090)
9. Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H (2009) Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci 1174:24-32
10. Barouch DH, Nabel GJ (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16(2):149-156 (Pubitemid 40344207)
11. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 115(11):3265-3275 (Pubitemid 41567591)
12. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G (2005) Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 174(7):4043-4050 (Pubitemid 40395980)
13. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic- T-cell responses is mediated by CD40 signalling. Nature 393(6684):478-480
14. Bond E, Adams WC, Smed-Sorensen A, Sandgren KJ, Perbeck L, Hofmann A, Andersson J, Lore K (2009) Techniques for time-Efficient isolation of human skin dendritic cell subsets and assessment of their antigen uptake capacity. J Immunol Methods 348(1-2):42-56
15. Bond E, Liang F, Sandgren KJ, Smed-Sorensen A, Bergman P, Brighenti S, Adams WC, Betemariam SA, Rangaka MX, Lange C, Wilkinson RJ, Andersson J, Lore K (2012) Plasmacytoid dendritic cells in fi ltrate the skin in positive tuberculin skin test indurations. J Invest Dermatol 132(1):114-123
16. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199(6):815-824 (Pubitemid 38375201)
17. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653):1881-1893
18. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C (2007) Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316(5824):612-616 (Pubitemid 46683149)
19. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9(5):558-566 (Pubitemid 351560525)
20. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29(9): 1812-1823
21. Casella CR, Mitchell TC (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65(20):3231-3240
22. Check E (2003) AIDS vaccines: back to 'plan A'. Nature 423(6943):912-914
23. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33(4):492-503
24. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM (2001) The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A 98(26):15191-15196 (Pubitemid 34013991)
25. Combadiere B, Vogt A, Mahe B, Costagliola D, Hadam S, Bonduelle O, Sterry W, Staszewski S, Schaefer H, Van der Werf S, Katlama C, Autran B, Blume-Peytavi U (2010) Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 5(5):e10818
26. Cooper CL, Davis HL, Morris ML, E fl er SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J (2004a) CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24(6):693-701 (Pubitemid 40933121)
27. Cooper CL, Davis HL, Morris ML, E fl er SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW (2004b) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix in fl uenza vaccine. Vaccine 22(23-24):3136-3143 (Pubitemid 39043651)
28. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, Boudinot P, Hosmalin A, Schwartz-Cornil I, Dalod M (2010) The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 207(6):1283-1292
29. De Gregorio E, Tritto E, Rappuoli R (2008) Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38(8):2068-2071
30. de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed SM, Radosevic K, Havenga MJ, Scheper RJ (2006) Intradermal delivery of adenoviral type-35 vectors leads to high ef fi ciency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. J Immunol 177(4):2208-2215 (Pubitemid 44200979)
31. Delamarre L, Mellman I (2011) Harnessing dendritic cells for immunotherapy. Semin Immunol 23(1):2-11
32. Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sorensen A, Seder RA, Karlsson Hedestam GB, Lore K (2009) Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 182(4):1991-2001
33. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, Van Nest G, Ott G, McDonald DM (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186(1):18-27 (Pubitemid 28285344)
34. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM, Ott G (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31(10):2910-2918 (Pubitemid 32994542)
35. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of de fi ned TLR ligands as adjuvants within human vaccines. Immunol Rev 239(1):178-196
36. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA (2002) Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76(5):2298-2305 (Pubitemid 34150698)
37. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA (2008) Crucial role for the Nalp3 in fl ammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198):1122-1126 (Pubitemid 351871731)
38. Fitzgerald-Bocarsly P, Dai J, Singh S (2008) Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 19(1):3-19
39. Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak V, Berthier-Vergnes O, de Saint- Vis B, Caux C, Dezutter-Dambuyant C, Lebecque S, Valladeau J (2006) Human Langerhans cells express a specific TLR pro fi le and differentially respond to viruses and Gram-positive bacteria. J Immunol 177(11):7959-7967 (Pubitemid 44846312)
40. Flacher V, Tripp CH, Stoitzner P, Haid B, Ebner S, Del Frari B, Koch F, Park CG, Steinman RM, Idoyaga J, Romani N (2010) Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 130(3):755-762
41. Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M, Gulati V, Winslow N, Gurwith M, Sinangil F, Berman PW (2003) Candidate HIV/AIDS vaccines: lessons learned from the World's fi rst phase III Efficacy trials. AIDS 17(2):147-156 (Pubitemid 36183039)
42. Freund J (1956) The mode of action of immunologic adjuvants. Bibl Tuberc 10:130-148
43. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9(11):1408-1412 (Pubitemid 37466191)
44. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, Williamson C, Birx D, Meyerhans A, Cox J, Hoelscher M (2007) CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 81(5):2440-2448
45. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP (2005) Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174(3):1259-1268
46. Gujer C, Sandgren KJ, Douagi I, Adams WC, Sundling C, Smed-Sorensen A, Seder RA, Hedestam GB, Lore K (2011a) IFN-alpha produced by human plasmacytoid dendritic cells enhances T cell-dependent naive B cell differentiation. J Leukoc Biol 89(6):811-821
47. Gujer C, Sundling C, Seder RA, Karlsson Hedestam GB, Lore K (2011b) Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134(3):257-269
48. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ (2003) A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21(19-20): 2461-2467 (Pubitemid 36561337)
49. Hartmann G, Marschner A, Viveros PR, Stahl-Hennig C, Eisenblatter M, Suh YS, Endres S, Tenner-Racz K, Uberla K, Racz P, Steinman RM, Ignatius R (2005) CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo. Vaccine 23(25):3310-3317 (Pubitemid 40523125)
50. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408(6813):740-745 (Pubitemid 32015992)
51. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat Immunol 3(2):196-200 (Pubitemid 34141451)
52. Hensley SE, Giles-Davis W, McCoy KC, Weninger W, Ertl HC (2005) Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 175(9):6032-6041 (Pubitemid 41508089)
53. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168(9):4531-4537 (Pubitemid 34441357)
54. Hou B, Reizis B, DeFranco AL (2008) Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 29(2):272-282
55. Iacobelli-Martinez M, Nemerow GR (2007) Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J Virol 81(3):1305-1312 (Pubitemid 46167851)
56. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, Steinman RM (2011) Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A 108(6):2384-2389
57. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S (2002) Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 195(11):1507-1512 (Pubitemid 34602828)
58. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987-995 (Pubitemid 41057715)
59. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31(11):3388-3393 (Pubitemid 33100532)
60. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2):225-234 (Pubitemid 37011337)
61. Jenne L, Schuler G, Steinkasserer A (2001) Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22(2):102-107 (Pubitemid 32667530)
62. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ (2010) Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207(6):1247-1260
63. Junt T, Scandella E, Ludewig B (2008) Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat Rev Immunol 8(10):764-775
64. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ (2001) Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 194(6):863-869 (Pubitemid 32983021)
65. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to in fl uenza virus. Nat Rev Microbiol 6(2):143-155
66. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, Munster D, MacDonald KP, Hart DN (2006) Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol 18(6):857-869 (Pubitemid 43983281)
67. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13(5):816-825
68. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373-384
69. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt A (2003) R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 100(14):8401-8406 (Pubitemid 36842557)
70. Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7(1):9-18 (Pubitemid 46020823)
71. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, Reiter Y, Banchereau J, Ueno H (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29(3):497-510
72. Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J (2010) Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 116(10):1685-1697
73. Kool M, Soullie T, Van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205(4):869-882 (Pubitemid 351549884)
74. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31(7):2154-2163 (Pubitemid 32640732)
75. Lahiri A, Das P, Chakravortty D (2008) Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26(52):6777-6783
76. Lahoud MH, Proietto AI, Ahmet F, Kitsoulis S, Eidsmo L, Wu L, Sathe P, Pietersz S, Chang HW, Walker ID, Maraskovsky E, Braley H, Lew AM, Wright MD, Heath WR, Shortman K, Caminschi I (2009) The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol 182(12):7587-7594
77. Lambrecht BN, Kool M, Willart MA, Hammad H (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21(1):23-29
78. Liard C, Munier S, Joulin-Giet A, Bonduelle O, Hadam S, Duffy D, Vogt A, Verrier B, Combadiere B (2011) Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 132(3 Pt 1):615-625
79. Lindsay RW, Darrah PA, Quinn KM, Wille-Reece U, Mattei LM, Iwasaki A, Kasturi SP, Pulendran B, Gall JG, Spies AG, Seder RA (2010) CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 185(3):1513-1521
80. Liu MA (2010) Immunologic basis of vaccine vectors. Immunity 33(4):504-515
81. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206(7):1589-1602
82. Lore K, Karlsson Hedestam GB (2009) Novel adjuvants for B cell immune responses. Curr Opin HIV AIDS 4(5):441-446
83. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, Roederer M, Seder RA, Koup RA (2003) Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 171(8):4320-4328 (Pubitemid 37238711)
84. Lore K, Smed-Sorensen A, VasudeVan J, Mascola JR, Koup RA (2005) Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 201(12):2023-2033 (Pubitemid 41002937)
85. Lore K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179(3):1721-1729
86. Maguire CA, Sapinoro R, Girgis N, Rodriguez-Colon SM, Ramirez SH, Williams J, Dewhurst S (2006) Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v) beta3 integrin Efficiently transduce human dendritic cells and enhance presentation of vectored antigens. Vaccine 24(5):671-682 (Pubitemid 43017834)
87. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9(4):287-293
88. Marsh M, Armes JE, Pelchen-Matthews A (1990) Endocytosis and recycling of CD4. Biochem Soc Trans 18(2):139-143 (Pubitemid 20135880)
89. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2010) New adjuvants for human vaccines. Curr Opin Immunol 22(3):411-416
90. McKay PF, Barouch DH, Santra S, Sumida SM, Jackson SS, Gorgone DA, Lifton MA, Letvin NL (2004) Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 34(4):1011-1020
91. McKee AS, Munks MW, Marrack P (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27(5):687-690 (Pubitemid 350102263)
92. McKee AS, MacLeod MK, Kappler JW, Marrack P (2010) Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol 8:37
93. McVey D, Zuber M, Ettyreddy D, Reiter CD, Brough DE, Nabel GJ, King CR, Gall JG (2010) Characterization of human adenovirus 35 and derivation of complex vectors. Virol J 7:276
94. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ (2008) Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 111(8):4245-4253
95. Mittag D, Proietto AI, Loudovaris T, Mannering SI, Vremec D, Shortman K, Wu L, Harrison LC (2011) Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol 186(11):6207-6217
96. Miyazawa N, Crystal RG, Leopold PL (2001) Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fi ber protein. J Virol 75(3):1387-1400 (Pubitemid 32094697)
97. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio E (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 105(30):10501-10506
98. Ni L, Gayet I, Zurawski S, Duluc D, Flamar AL, Li XH, O'Bar A, Clayton S, Palucka AK, Zurawski G, Banchereau J, Oh S (2010) Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses. J Immunol 185(6):3504-3513
99. O'Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, Rolnitzky L, Markowitz M, Margolis DM, Levy D, Bhardwaj N (2011) Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells de fi nes a persistently IFN-alpha-producing and partially matured phenotype. J Clin Invest 121(3):1088-1101
100. Offringa R, Kwappenberg K, Rabelink M, Rea D, Hoeben R (2005) Adenoviral transduction of dendritic cells. Methods Mol Med 109:83-96
101. O'Hagan DT (2007) MF59 is a safe and potent vaccine adjuvant that enhances protection against in fl uenza virus infection. Expert Rev Vaccines 6(5):699-710 (Pubitemid 47607847)
102. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G (2011) MF59 adjuvant: the best insurance against in fl uenza strain diversity. Expert Rev Vaccines 10(4):447-462
103. Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yuksel S, Osterhaus AD, Havenga MJ (2004) An adenoviral type 5 vector carrying a type 35 fi ber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22(23-24):3035-3044 (Pubitemid 39037205)
104. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, Van Hoogevest P, Van Nest G (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277-296
105. Palucka K, Banchereau J, Mellman I (2010) Designing vaccines based on biology of human dendritic cell subsets. Immunity 33(4):464-478
106. Papagatsias T, Rozis G, Athanasopoulos T, Gotch F, Dickson G, Patterson S (2008) Activity of different vaccine-associated promoter elements in human dendritic cells. Immunol Lett 115(2): 117-125
107. Pelchen-Matthews A, Clapham P, Marsh M (1995) Role of CD4 endocytosis in human immunodeficiency virus infection. J Virol 69(12):8164-8168
108. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bardelli M, Montagna D, Locatelli F, Wack A (2007) Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 109(12):5371-5379 (Pubitemid 46890559)
109. Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7): 1055-1065
110. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis e Sousa C (2010) Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 207(6):1261-1271
111. Qi H, Egen JG, Huang AY, Germain RN (2006) Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 312(5780):1672-1676 (Pubitemid 43902670)
112. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203(2):413-424 (Pubitemid 43290850)
113. Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25(12): 1361-1366 (Pubitemid 350233122)
114. Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE, Melief CJ, Offringa R (1999) Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 73(12):10245-10253
115. Rea D, Havenga MJ, Van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R (2001) Highly Efficient transduction of human monocyte-derived dendritic cells with subgroup B fi ber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 166(8):5236-5244 (Pubitemid 32280740)
116. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220
117. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393(6684):474-478
118. Robinson MJ, Osorio F, Rosas M, Freitas RP, Schweighoffer E, Gross O, Verbeek JS, Ruland J, Tybulewicz V, Brown GD, Moita LF, Taylor PR, Reis e Sousa C (2009) Dectin-2 is a Sykcoupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med 206(9):2037-2051
119. Romani N, Ebner S, Tripp CH, Flacher V, Koch F, Stoitzner P (2006) Epidermal Langerhans cells - changing views on their function in vivo. Immunol Lett 106(2):119-125 (Pubitemid 44223748)
120. Romani N, Thurnher M, Idoyaga J, Steinman RM, Flacher V (2010) Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine Efficacy. Immunol Cell Biol 88(4):424-430
121. Roukens AH, Gelinck LB, Visser LG (2012) Intradermal vaccination to protect against yellow fever and in fl uenza. Curr Top Microbiol Immunol 351:159-179
122. Sabado RL, Babcock E, Kavanagh DG, Tjomsland V, Walker BD, Lifson JD, Bhardwaj N, Larsson M (2007) Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1. Eur J Immunol 37(7):1752-1763 (Pubitemid 47065115)
123. Schoenberger SP, Toes RE, Van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684):480-483
124. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C (2000) CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13(4):453-462
125. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P, P fi ster T, Maurer P, Bachmann MF, Graf N, Kundig TM (2009) Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergenspecific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 39(4):562-570
126. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A (2008) The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180(8):5402-5412
127. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3(11):e169
128. Shortman K, Liu YJ (2002) Mouse and human dendritic cell subtypes. Nat Rev Immunol 2(3): 151-161 (Pubitemid 37336516)
129. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284(5421):1835-1837
130. Smed-Sorensen A, Lore K, VasudeVan J, Louder MK, Andersson J, Mascola JR, Spetz AL, Koup RA (2005) Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol 79(14):8861-8869 (Pubitemid 40934796)
131. Sogaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schonheyder HC, Ostergaard L (2010) Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a Toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 51(1):42-50
132. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Muller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5(4):e1000373
133. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336(2):86-91 (Pubitemid 27020884)
134. Sumida SM, McKay PF, Truitt DM, Kishko MG, Arthur JC, Seaman MS, Jackson SS, Gorgone DA, Lifton MA, Letvin NL, Barouch DH (2004) Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114(9):1334-1342 (Pubitemid 40385305)
135. Sun H, Pollock KG, Brewer JM (2003) Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21(9-10):849-855 (Pubitemid 36131100)
136. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7(10):790-802 (Pubitemid 47480309)
137. Tacken PJ, Joosten B, Reddy A, Wu D, Eek A, Laverman P, Kretz-Rommel A, Adema GJ, Torensma R, Figdor CG (2008) No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. J Immunol 180(11):7687-7696
138. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A (2011) Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 118(15):4111-4119
139. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, Haynes K, Steele C, Botto M, Gordon S, Brown GD (2007) Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 8(1):31-38 (Pubitemid 46242356)
140. Teleshova N, Kenney J, Van Nest G, Marshall J, Lifson JD, Sivin I, Dufour J, Bohm R, Gettie A, Robbiani M (2006) Local and systemic effects of intranodally injected CpG-C immunostimulatory- oligodeoxyribonucleotides in macaques. J Immunol 177(12):8531-8541 (Pubitemid 44893815)
141. Teunissen MB, Haniffa M, Collin MP (2012) Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design. Curr Top Microbiol Immunol 351:25-76
142. Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, Huang Y, Schlesinger SJ, Park CG, Nussenzweig MC, Granelli-Piperno A, Steinman RM (2006) Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 203(3):607-617
143. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM (2012) Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 271(2):183-192
144. Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ, Keler T, Odunsi K, Old LJ, Ritter G, Gnjatic S (2011) Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol 186(2):1218-1227
145. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, Clark G, Hart D, Cunningham AL (2001) HIV gp120 receptors on human dendritic cells. Blood 98(8):2482-2488
146. Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW, Cunningham AL (2002) Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 3(10):975-983 (Pubitemid 35154012)
147. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stossel H, Romani N, Piatak M Jr, Lifson JD, Pope M, Cunningham AL (2004) Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103(6):2170-2179 (Pubitemid 38326235)
148. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, Palucka K (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234(1):199-212
149. Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, Zurawski S, Zurawski G, Palucka K, Banchereau J, Oh S (2011) Targeting human dendritic cell subsets for improved vaccines. Semin Immunol 23(1):21-27
150. Van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MB (2007) Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 178(4):1986-1990 (Pubitemid 46233394)
151. Van der Aar AM, de Groot R, Sanchez-Hernandez M, Taanman EW, Van Lier RA, Teunissen MB, de Jong EC, Kapsenberg ML (2011) Cutting edge: virus selectively primes human Langerhans cells for CD70 expression promoting CD8+ T cell responses. J Immunol 187(7):3488-3492
152. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34(1):251-262 (Pubitemid 38111541)
153. Wang G, Liszewski MK, Chan AC, Atkinson JP (2000) Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation. J Immunol 164(4):1839-1846 (Pubitemid 30108737)
154. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA (2005a) HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 102(42):15190-15194 (Pubitemid 41513357)
155. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA (2005b) Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 174(12):7676-7683 (Pubitemid 40806272)
156. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA (2006) Toll-like receptor agonists Influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203(5):1249-1258 (Pubitemid 43736594)
157. Zehner M, Chasan AI, Schuette V, Embgenbroich M, Quast T, Kolanus W, Burgdorf S (2011) Mannose receptor polyubiquitination regulates endosomal recruitment of p97 and cytosolic antigen translocation for cross-presentation. Proc Natl Acad Sci U S A 108(24):9933-9938
158. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM (1999) Recombinant adenovirus is an Efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29(3):964-972 (Pubitemid 29119077)